累及升主动脉并延伸至降胸主动脉的壁内血肿的治疗结局
该回顾性研究纳入135例急性IMH累及升主动脉并延伸至降胸主动脉的患者,比较降胸主动脉TEVAR(104例)与药物治疗(31例)的结局。TEVAR组1、3、5年无不良主动脉事件率(89.2%、88.2%、84.0%)和生存率(100%)均显著优于药物治疗组,肾功能不全是药物治疗组不良事件的独立危险因素。
要点
- 降胸主动脉TEVAR较药物治疗显著提高无不良主动脉事件率和生存率。
- 药物治疗组肾功能不全是不良主动脉事件的独立危险因素(HR 8.691)。
- 对累及升主动脉并延伸至降胸主动脉的IMH,TEVAR可能是更优选择。
核心结论
- 与药物治疗相比,降胸主动脉TEVAR可能是累及升主动脉并延伸至降胸主动脉的IMH更有利的治疗方式。
- 肾功能不全患者更易发生不良主动脉事件,提示需要后续干预或死亡风险增加。
研究设计与样本
- 回顾性分析2012年1月至2019年12月诊断为急性IMH累及升主动脉并延伸至降胸主动脉的全部患者。
- 共纳入135例患者,其中104例接受降胸主动脉TEVAR(组1),31例接受药物治疗(组2)。
主要发现
- TEVAR组1、3、5年无不良主动脉事件率分别为89.2%、88.2%、84.0%,药物治疗组分别为74.2%、74.2%、74.2%(P = .026)。
- TEVAR组1、3、5年生存率均为100%,药物治疗组分别为93.5%、93.5%、81.9%(P = .002)。
- 药物治疗组中发生不良主动脉事件者肾功能不全比例更高(55.6% vs 9.1%;P = .003)。
- 药物治疗组多因素分析显示肾功能不全是唯一独立危险因素(HR 8.691;95%CI 2.056-36.737;P = .003)。
关键数值与推荐
- 主要终点为随访期间主动脉疾病相关死亡和需要手术或血管内治疗的不良主动脉相关事件(如主动脉破裂、主动脉疾病进展或内漏)。
临床怎么用
- 对累及升主动脉并延伸至降胸主动脉的急性IMH,可考虑降胸主动脉TEVAR以降低不良事件和死亡风险。
- 合并肾功能不全的IMH患者接受药物治疗时需密切监测,因其不良主动脉事件风险显著增高。
局限性
- 本研究为回顾性分析,样本来自单中心,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal treatment of intramural hematoma (IMH) involving the ascending aorta remains controversial. This study aimed to analyze the results of the management of patients with acute IMH involving the ascending aorta and extending into the descending thoracic aorta, to compare outcomes of descending thoracic endovascular aortic repair (TEVAR) with that of medical therapy (MT), and to assess the risk factors associated with adverse aortic events. METHODS: We retrospectively analyzed all patients diagnosed with acute IMH involving the ascending aorta and extending into the descending thoracic aorta from January 2012 to December 2019. The primary end points during follow-up were aortic disease-related death and adverse aorta-related events that required surgical or endovascular treatment, such as aortic rupture, the progression of aortic disease, or endoleak. RESULTS: We identified a total of 135 patients with acute IMH involving the ascending aorta and extending into the descending thoracic aorta, of whom 104 underwent descending TEVAR (group 1) and 31 were managed with MT (group 2). Freedom from adverse aorta-related events at 1, 3, and 5 years was significantly higher for patients who underwent descending TEVAR compared with those managed with MT (89.2%, 88.2%, and 84.0% vs 74.2%, 74.2%, and 74.2%, respectively; P = .026). The 1-, 3-, and 5-year survival rates for patients in the descending TEVAR group was 100%, 100%, and 100%, respectively, which was significantly higher than the survival of the MT group: 93.5%, 93.5%, and 81.9%, respectively (P = .002). On a univariate analysis among patients receiving MT, those who suffered adverse aorta-related events showed a higher prevalence of renal insufficiency (55.6% vs 9.1%; P = .003). In MT patients, multivariate analysis showed that renal insufficiency was the only independent risk factor associated with adverse aorta-related events (hazard ratio, 8.691; 95% confidence interval, 2.056-36.737; P = .003). CONCLUSIONS: Based on our study, compared with MT, descending TEVAR might be the more favorable treatment for patients with IMH involving the ascending aorta and extending into the descending thoracic aorta. Patients with renal insufficiency are more likely to experience adverse aorta-related events, which implies the need for subsequent intervention or an increased risk of mortality. The risk factor would be helpful for clinical decision-making.
引用
- Li J, Xia L, Ma M, et al. Outcomes of intramural hematoma involving the ascending aorta and extending into the descending thoracic aorta. J Vasc Surg. 2021. PMID: 34481899. doi:10.1016/j.jvs.2021.07.231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。